×

Crystalline forms of AP26113, and preparation method thereof

  • US 10,544,129 B2
  • Filed: 10/25/2017
  • Issued: 01/28/2020
  • Est. Priority Date: 10/25/2016
  • Status: Active Grant
First Claim
Patent Images

1. A crystalline form CS2 of brigatinib, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 17.1°

  • ±

    0.2°

    , 22.9°

    ±

    0.2° and

    28.7°

    ±

    0.2°

    using CuKα

    radiation.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×